Survodutide Timeline Boehringer Ingelheims SYNCHRONIZE program includes multiple Phase 3 trials: SYNCHRONIZE-1: Obesity without type 2 diabetes (726 participants, 76 weeks) SYNCHRONIZE-2: Obesity with type 2 diabetes (755 participants, 76 weeks) SYNCHRONIZE-CVOT: Cardiovascular outcomes (4,935 participants target) LIVERAGE trials: MASH-specific studies initiated October 2024 FDA Breakthrough Therapy designation for MASH may accelerate review for that indication specifically
Let's use this diabetes drug on non-diabetics and make them reliant on it, because they won't be able to bear gaining the weight back on!" Pharmaceutical companies: "Oh woopsie, the massive demand drove up the cost of Ozempic and now diabetics can't afford it " *rolls in 500 billion dollars of market value * Ozempic, and other weight loss drugs, needs to be tightly regulated
Step 2: The Math Precision is Everything This is where many people get intimidated, but it's just simple ratio math
It also sounds too good to be true, because in most cases, it is
Psychotropic drug utilization patterns in pregnant women with bipolar disorder: a 16-year population-based cohort study
